NasdaqGS:XERSPharmaceuticals
Xeris Biopharma (XERS): Assessing Valuation as Investors Back Its Shift to Profitable Specialty Pharma
Recent analysis suggests Xeris Biopharma Holdings (XERS) is shifting from survival mode to a profit focused specialty pharma story, with three commercial drugs and a growing pipeline reshaping how investors view the stock.
See our latest analysis for Xeris Biopharma Holdings.
That improving story is already showing up in the tape, with the share price at $7.34 after a 1 day share price return of 4.71 percent and a powerful year to date share price return of 112.14 percent. The 3 year total...